These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1966729)

  • 21. Role of thromboxane and serotonin as mediators in the development of spontaneous alterations in coronary blood flow and neointimal proliferation in canine models with chronic coronary artery stenoses and endothelial injury.
    Willerson JT; Eidt JF; McNatt J; Yao SK; Golino P; Anderson HV; Buja LM
    J Am Coll Cardiol; 1991 May; 17(6 Suppl B):101B-110B. PubMed ID: 2016468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serotonin and thrombotic complications.
    Willerson JT
    J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S13-20. PubMed ID: 1717768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiology of blood platelet activation.
    Rao GH
    Indian J Physiol Pharmacol; 1993 Oct; 37(4):263-75. PubMed ID: 8112802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet function in intravascular device implant-induced intimal injury.
    Tesfamariam B
    Cardiovasc Revasc Med; 2008; 9(2):78-87. PubMed ID: 18486081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquisition and aggregation of canine blood platelets: basic mechanisms of function and differences because of breed origin.
    Clemmons RM; Meyers KM
    Am J Vet Res; 1984 Jan; 45(1):137-44. PubMed ID: 6422804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular effects of serotonin and ischemia.
    Vanhoutte PM
    J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S15-9. PubMed ID: 1369711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotonin and preactivated platelets in essential hypertension.
    Bühler FR; Amstein R; Fetkovska N
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S32-4. PubMed ID: 2446066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Platelets, coagulation, and fibrinolysis in atherosclerosis formation].
    Ishii H; Yoshida M
    Nihon Rinsho; 2011 Jan; 69(1):50-4. PubMed ID: 21226260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction.
    Parise P; Hauert J; Iorio A; Callegari P; Agnelli G
    J Lab Clin Med; 1995 Feb; 125(2):212-21. PubMed ID: 7531212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
    Takiguchi Y; Asai F; Wada K; Nakashima M
    Thromb Haemost; 1995 Apr; 73(4):683-8. PubMed ID: 7495079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The role of serotonin in haemostasis].
    Duerschmied D; Bode C
    Hamostaseologie; 2009 Nov; 29(4):356-9. PubMed ID: 19882076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of serotonin in arteriolar thrombosis and secondary vasospasm.
    Drouet L; Bal Dit Sollier C; Ruton S; Pignaud G
    J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S49-53. PubMed ID: 1369719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human platelets in vitro.
    De Clerck F; Xhonneux B
    Agents Actions; 1986 Mar; 17(5-6):515-26. PubMed ID: 2939698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Restoration of post-thrombotic peripheral collateral circulation in the cat by ketanserin, a selective 5-HT2-receptor antagonist.
    Nevelsteen A; De Clerck F; Loots W; De Gryse A
    Arch Int Pharmacodyn Ther; 1984 Aug; 270(2):268-79. PubMed ID: 6486973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotonergic type-2 (5-HT2) antagonists: a novel class of cardiovascular drugs.
    Robertson JI
    J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S48-53. PubMed ID: 1717773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of naftidrofuryl, a 5-HT2 antagonist, on collateral vascular responses to serotonin and to platelet activation.
    Hollenberg NK; Nie Q
    J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S36-9. PubMed ID: 1369716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of platelet activation and fibrin formation in thrombogenesis.
    Vermylen J; Verstraete M; Fuster V
    J Am Coll Cardiol; 1986 Dec; 8(6 Suppl B):2B-9B. PubMed ID: 3537069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of serotonergic antagonism on local responses to an acute and selective endothelial trauma in vivo.
    Herrmann KS; Kreuzer H
    J Cardiovasc Pharmacol; 1990; 16 Suppl 3():S40-4. PubMed ID: 1369717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet-vessel wall interactions in hemostasis: implication of 5-hydroxytryptamine.
    De Clerck F; Somers Y; Van Gorp L
    Agents Actions; 1984 Dec; 15(5-6):627-35. PubMed ID: 6543415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thromboxane A2 and serotonin mediate coronary blood flow reductions in unsedated dogs.
    Eidt JF; Ashton J; Golino P; McNatt J; Buja LM; Willerson JT
    Am J Physiol; 1989 Sep; 257(3 Pt 2):H873-82. PubMed ID: 2782444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.